Fibrinogen single-component sealant - PPL Therapeutics

Drug Profile

Fibrinogen single-component sealant - PPL Therapeutics

Alternative Names: Fibrin 1 sealant - PPL Therapeutics; Fibrin I; Fibrinogen - PPL Therapeutics; Single-component fibrin sealant - PPL Therapeutics

Latest Information Update: 27 Jun 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Acute-phase proteins; Antihaemorrhagics; Blood coagulation factors; Coagulants
  • Mechanism of Action Fibrinogen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Blood coagulation disorders; Wounds

Most Recent Events

  • 14 May 2003 PPL Therapeutics will now seek approval for fibrin I as a device
  • 19 Feb 2001 This product is available for licensing in USA, Europe and Japan (
  • 19 Feb 2001 Preclinical development for Coagulation disorders in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top